Va1 Seven, Ten or Thirteen? The Cost-Utility of Infant Vaccination With a 7-, 10- Or 13-Valent Pneumococcal Conjugate Vaccine in the Netherlands

Vemer, Pepijn; Greeff, Scd de; Schouls, L. M.; Al, MJ; Melker, H de

doi:10.1016/s1098-3015(10)74112-7

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ante la disponibilidad de la PCV-10 y la PCV-13, se han llevado a cabo evaluaciones económicas en diversos contextos nacionales, tales como Holanda [37], Grecia [38], Alemania [39], Canadá [40], Reino Unido [41] y México [16].…”

Section: Discussionunclassified

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

et al. 2011

View full text Add to dashboard Cite

show abstract

“…4.3%) [28]. Vaccine efficacy against all-cause (excluding NTHi) pneumonia hospitalizations was estimated as 17.7%, 22.9% and 24.7% for the 7-, 10- and 13-valent vaccines, respectively, as described in a previous health economic analysis of PCVs in the Netherlands [29]. For PHiD-CV, an additional efficacy against hospitalized all-cause pneumonia (1.068%) was also included to account for the vaccine’s potential efficacy against NTHi.…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model

Bakır

Türel²,

Topachevskyi

2012

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundStreptococcus pneumoniae infections, which place a considerable burden on healthcare resources, can be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with that of PCV-7 in Turkey.MethodsA cost-utility analysis was conducted and a decision analytical model was used to estimate the proportion of the Turkish population <10 years old that would experience 10 mutually exclusive outcomes over the course of 1 year from a perspective of a healthcare system. Model outcomes were adjusted according to the population demographics and region-specific serotype distribution in Turkey. Health outcomes and direct healthcare costs were simulated for PCV-7, PCV-13 and PHiD-CV.ResultsPCV-13 and PHiD-CV are projected to have a substantial impact on pneumococcal disease in Turkey versus PCV-7, with 2,223 and 3,156 quality-adjusted life years (QALYs) and 2,146 and 2,081 life years, respectively, being saved under a 3+1 schedule. Projections of direct medical costs showed that a PHiD-CV vaccination programme would provide the greatest cost savings, offering additional savings of US$11,718,813 versus PCV-7 and US$8,235,010 versus PCV-13. Probabilistic sensitivity analysis showed that PHiD-CV dominated PCV-13 in terms of QALYs gained and cost savings in 58.3% of simulations.ConclusionUnder the modeled conditions, PHiD-CV would provide the most cost-effective intervention for reducing pneumococcal disease in Turkish children.

show abstract

“…[ 40 41 42 ] Pneumococcal vaccine gives protection not only against pneumonia but also other diseases like meningitis, otitis media, and bacteremia also. [ 24 ] Globally 160 countries have included Hib vaccine in national immunization schedule. [ 43 ] Indian government has already started inclusion of Hib vaccine (in the form of Pentavac) as pilot project in eight states (Tamil Nadu, Kerala, Haryana, Jammu and Kashmir, Gujarat, Karnataka, Goa, Pondicherry) of India.…”

Section: Why Hib or Pneumococcal Vaccine Should Be Included In Uip Ofmentioning

confidence: 99%

“…[ 24 ] Globally 160 countries have included Hib vaccine in national immunization schedule. [ 43 ] Indian government has already started inclusion of Hib vaccine (in the form of Pentavac) as pilot project in eight states (Tamil Nadu, Kerala, Haryana, Jammu and Kashmir, Gujarat, Karnataka, Goa, Pondicherry) of India. [ 44 ] Given the experiences from other countries Hib and Pentavac should be considered for developing country like India.…”

Section: Why Hib or Pneumococcal Vaccine Should Be Included In Uip Ofmentioning

confidence: 99%

Four new vaccines for routine immunization in India: What about hemophilus influenza B and pneumococcal vaccine?

Paul

Sahoo

2015

J Family Med Prim Care

View full text Add to dashboard Cite

Immunization is the process whereby a person is made immune or resistant to an infectious disease, typically by the administration of a vaccine. The Expanded Program on Immunization (EPI) was flagged off in India in 1978. According to the recommendation of National technical advisory group of India (NATGI), Government of India is going to include four new vaccines in the UIP for whole India. The four new vaccines are Inactivated Poliomyelitis Vaccine (IPV) for polio, rota viral vaccine, vaccine against rubella, and Japanese encephalitis vaccine (179 districts in India). Here, authors have tried to show a comparative descriptive analysis of the hemophilus influenza and pneumococcal pneumonia with rota virus, so that in near future Government of India can also consider their inclusion in the national UIP. In India, 39.2% of all diarrheal death are due to rota virus, whereas 0.72 million deaths are due to hemophilus influenza B and 1.3 million are due to pneumococcal pneumonia in <5 years age-group. India's indigenous developed rota viral vaccine's (Rotavac) efficacy is 56% in 1st year compared to H influenza B (Hib) efficacy 95% and PCV13 vaccine “3 + 1” dose efficacy 100% (South Africa). Rotarix incremental cost-effectiveness ratio is US $21.4 to US $34 per disability-adjusted life years (DALYs) compared to Hib US $ 819 per DALYs in India. In case of pneumococcal vaccine, India needs more trails on the serotype specificity, efficacy, and cost-effectiveness but there is enough evidence that hemophilus influenza burden is high in India and the present Hib vaccine is safe and highly effective. In future with the help of donor agencies, India should include the hemophilus influenza B and pneumococcal pneumonia vaccine in national UIP which will save millions of poor children's life.

show abstract

Va1 Seven, Ten or Thirteen? The Cost-Utility of Infant Vaccination With a 7-, 10- Or 13-Valent Pneumococcal Conjugate Vaccine in the Netherlands

Cited by 6 publications

References 0 publications

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model

Four new vaccines for routine immunization in India: What about hemophilus influenza B and pneumococcal vaccine?

Contact Info

Product

Resources

About